TY - JOUR T1 - Reversible posterior leukencephalopathy syndrome induced by granulocyte stimulating factor filgrastim JF - Journal of Neurology, Neurosurgery & Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 280 LP - 281 DO - 10.1136/jnnp.69.2.280 VL - 69 IS - 2 AU - T LENIGER AU - O KASTRUP AU - HC DIENER Y1 - 2000/08/01 UR - http://jnnp.bmj.com/content/69/2/280.abstract N2 - Posterior leukencephalopathy syndrome is characterised by visual disturbances, altered mental status, drowsiness, seizures, headache, and occasionally focal neurological signs. It is usually associated with severe hypertension and has most often been seen in patients treated with immunsuppressive drugs such as cyclosporin A, tacrolimus, and interferon-α.1 2 The granulocyte and granulocyte macrophage stimulating factor filgrastim (Neupogen®) is used in chemotherapy induced bone marrow suppression. By contrast with molgramostim (Leukomax®) filgrastim is supposed to have fewer CNS side effects. Intracranial hypertension and convulsions have been reported after molgrastim therapy. Only one case of recurring encephalopathy and focal status epilepticus due to filgrastim is published.3 In that case the contrast enhanced CT was normal.We report a case of reversible posterior leukencephalopathy syndrome with transient bilateral changes … ER -